–
27 different customers representing North America and Europe
–
31 oral presentations across four consecutive days
–
Topics span the application of OGM in genetic disease and cancer research
–
45% of presentations are from North America and 55% are from Europe
SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr
®
system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced its Symposium lineup of 31 oral presentations delivered from 27 different customers worldwide featuring the utility of OGM across a wide range of applications for genetic disease and cancer research. In all, 45% of the customer presentations at Symposium are from North America while 55% are from Europe. Symposium will take place virtually from January 10 to 13, 2022. During these four days, customers will showcase their latest research findings using OGM in constitutional cytogenomics, hematologic malignancies, solid tumors and in combination with next-generation sequencing (NGS). Each day will feature oral customer presentations, a live panel with Q&A and a scientific poster exhibit within the virtual exhibition hall.
“We believe Symposium is the quintessential event for the OGM community to come together and share the progress they are making and their ideas for expanding the utility of OGM,” said Erik Holmlin, PhD, President and CEO of Bionano Genomics. “Last year we were impressed by the utility, scope and breath of applications presented by our customers using the Saphyr system. Symposium is an opportunity for anyone interested or currently working with OGM to form connections within the community and see the potential impact of looking at the genome in a different way. Bionano is dedicated to elevating human health by transforming the way the world sees the genome and I’m greatly looking forward to seeing our customers showcase their accomplishments with OGM at Symposium. We also plan on conducting a Symposium in China later this year to bring together our Asia Pacific customers to feature their accomplishments using OGM.”
“Symposium in 2021 marked a historic event where OGM users showcased their data. Since then, we have made significant improvements in OGM workflow and data analysis which have allowed our customers around the world to advance their clinical and translational research. We have seen the implementation of our Saphyr system across a broad range of clinical research applications for consolidating traditional cytogenetics workflows to OGM as well as demonstrating its utility in combination with NGS,” said Alka Chaubey, PhD, FACMG, Chief Medical Officer at Bionano. “Symposium attendees have an opportunity to learn from their peers and we will continue to provide our customers with the training, education and services to support our goal of making OGM the standard of care.”
Each session of Symposium will start at 8:00 am PST and will last approximately 5 hours. After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey. In addition, each day will feature a scientific poster exhibit. Below is the list of customer presentations per day and application area.
|
January 10: Constitutional Cytogenomics |
|||
|
Speaker Name |
Institution |
State / Country |
Talk Title |
| Chaim Jalas | The Foundation for Embryonic Competence | New Jersey, USA | Validation of Optical Genome Mapping for Preimplantation Genetic Analysis – Structural Rearrangement (PGD-SR) Applications |
| Dr. Laila El-Khattabi | Assistance Publique–Hôpitaux de Paris (AP-HP) – Université de Paris | Paris, France | Balanced Translocations Associated with Male Infertility: How Optical Genome Mapping Could Lead to New Discoveries? |
| Dr. Shirley Heggarty | Belfast Health and Social Care Trust | Belfast, UK | Clinical Utility of Optical Genome Mapping in a Constitutional Cytogenetics Laboratory |
| Dr. Alexander Hoischen | Radboud University Medical Center | Nijmegen, Netherlands | Optical Genome Mapping: Mapping Difficult Structural Variant Types – Repeat Expansions |
| Dr. Anwar Iqbal | University of Rochester Medical Center | New York, USA | Validation Study of Optical Genome Mapping for Postnatal and Prenatal Clinical Research According to Established NYSDOH Guidelines |
| Dr. Nikhil Sahajpal | Augusta University | Georgia, USA | Enhanced Structural Variation Detection with OGM in Constitutional Disorders |
|
January 11: Hematologic Malignancies |
|||
|
Speaker Name |
Institution |
State / Country |
Talk Title |
| Bence Dvorak | University Children’s Hospital Zurich- Eleonore Foundation | Zurich, Switzerland | Characterization of Plasma Cell Dyscrasias (PCD) by Optical Genome Mapping |
| Dr. Jonathan L. Lühmann | Hannover Medical School | Hannover, Germany | The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia |
| Dr. Anna Puiggros | Hospital del Mar | Barcelona, Spain | The Hidden Side of Genomic Complexity: Learning from OGM in Chronic Lymphocytic Leukemia |
| Dr. Barbara Dewaele | University Hospitals Leuven | Leuven, Belgium | Opportunities of Optical Genome Mapping for Genetic Diagnosis in Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia |
| Dr. Kornelia Neveling | Radboud University Medical Center | Nijmegen, Netherlands | Technical and Clinical Validation of Optical Genome Mapping |
| Dr. Elena García Sánchez | Hospital Infantil Universitario Niño Jesús | Madrid, Spain | Optical Genome Mapping for Diagnosis of Paediatric Leukaemia |
| Dr. Brynn Levy | Columbia University Medical Center | New York, USA | Assessing Genomic Aberrations in AML using Optical Genome Mapping: Insights from a National Multi-Center Study |
| Dr. Adrian Dubuc | Harvard Medical School Brigham and Women’s Hospital | Massachusetts, USA | Shining a New Light on Cancer Cytogenetics: Leveraging Novel Technological Approaches for Improved Understanding in B-ALL |
| Dr. Adam C. Smith | Laboratory Medicine Program, University Health Network, University of Toronto | Toronto, Canada | A Year in Review: Parallel Testing of Hematologic Malignancies Using Optical Genome Mapping Compared to Conventional Cytogenetics |
| Dr. Saurabh Gupta | Quest Diagnostics | New Jersey, USA | Optical genome mapping: Utility for stratification of B-CLL by accurate identification of clinically relevant structural variants |
|
January 12: Solid Tumors |
|||
|
Speaker Name |
Institution |
Talk Title |
|
| Dr. Elena García Sánchez | Hospital Infantil Universitario Niño Jesús | Madrid, Spain | Optical Genome Mapping: Application for Analysis of Non-Haematological Cancers |
| Dr. Tuomo Mantere | University of Oulu, Finland | Oulu, Finland | Optical Genome Mapping in Unexplained High-Risk Breast Cancer Families |
| Dr. Gopalrao Velagaleti | UT Health – San Antonio | Texas, USA | Vigor and Reproducibility in Research: The Cell Line Saga: Is OGM the Answer? |
| Dr. Matthew Brian Couger | Brigham and Women’s Hospital | Massachusetts, USA | The Chromosomal Landscape of Mesothelioma |
| Dr. Juan Diaz Martin | Instituto de Biomedicina de Sevilla (IBiS) | Sevilla, Spain | Complex Rearrangement Patterns in Undifferentiated Small Round Cell Sarcomas Associated with Poor Outcomes in Clinical Research |
| Dr. Ravindra Kolhe | Medical College of Georgia at Augusta University | Georgia, USA | Utility of Optical Genome Mapping for the Chromosomal Characterization of Solid Tumors |
|
January 13: OGM + NGS |
|||
|
Speaker Name |
Institution |
Talk Title |
|
| Dr. Kornelia Neveling | Radboud University Medical Center | Nijmegen, Netherlands | Optical Genome Mapping: Different Types of Hidden SV’s in Families with Inherited Retinal Diseases |
| Dr. Mariangela Sabatella | Princess Máxima Center for Pediatric Oncology | Utrecht, Netherlands | Enlightening the Dark Matter of the Genome: OGM Identifies a Germline Retrotransposon Insertion in SMARCB1 in Two Siblings with Atypical Teratoid Rhabdoid Tumors |
| Dr. Gordana Raca | Children’s Hospital Los Angeles | California, USA | OGM and Capture-Based RNA-Seq Enable Comprehensive Genomic Characterization of Pediatric B-lymphoblastic Leukemias |
| Arran Constantine | bit.bio | Cambridge, UK | Cytogenetic QC at bit.bio: How a Next-Generation Cytogenetics Platform Enhances Quality Control of Next-Generation Cells |
| Dr. Saumyaa Saumyaa | AstraZeneca | Cambridge, UK | Detection and Characterization of On- and Off-target Integration of Foreign DNA in the Host Genomes, for Therapeutic Cell and Gene Therapy Development, Using OGM |
| Dr. Laila El-Khattabi | Assistance Publique–Hôpitaux de Paris (AP-HP) – Université de Paris | Paris, France | Molecular Characterization of Genome Structural Variants in Developmental Disorders: Comparison Between OGM and Short Read WGS |
| Dr. Jens Luebeck | University of California, San Diego | California, USA | Combined NGS and OGM Reveal the Complex Structures of Circular Extrachromosomal DNA and other Focal Amplifications in Cancer Genomes |
| Dr. Ravindra Kolhe | Medical College of Georgia at Augusta University | Georgia, USA | Clinical Utility of Combined Optical Genome Mapping and Comprehensive Genomic Sequencing in Robust Evaluation of Hematological Cancers |
| Dr. Rashmi Kanagal Shamana | MD Anderson Cancer Center | Texas, USA | A Comprehensive Assessment of a Large MDS Cohort at MD Anderson Cancer Center Using Optical Genome Mapping and a Targeted NGS Panel |
Symposium registration is open to all and there is no charge for attending this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit
www.bionanogenomics.com
,
www.lineagen.com
or
www.biodiscovery.com
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits of the Symposium, our plans to conduct a Symposium in China later this year, and the potential for OGM to become the standard of care. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape, including the introduction of competitive technologies or improvements in existing technologies; failure of future study results to support those demonstrated during the presentations referenced in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
[email protected]
Media Relations:
Michael Sullivan
Seismic
+1 (503) 799-7520
[email protected]
